Covalon Technologies Ltd. (the "Company" or "Covalon")
(TSXV:COV; OTCQX:CVALF) is pleased to announce that
its MediClear™ PreOp product has been recognized by
both the medical device industry and by key clinicians as an
important innovation in the fight to
prevent surgical site infections.
Surgical site infections (“SSIs”) are among the costliest of
healthcare-associated infections and are the second most common in
the US.1, 2, 3 SSIs can lead to prolonged patient suffering,
extended hospitalizations, and, in some cases, patient death. SSIs
cost the healthcare industry billions of dollars each year, much of
which is no longer reimbursable through medical insurance providers
in the United States.
MediClear PreOp, the only dual antimicrobial pre-surgical
film barrier, was designed to help hospitals reduce infections by
protecting surgical sites on patients before a surgical procedure.
MediClear PreOp reduces the level of pathogens on the
patient’s skin while protecting the surgical site from exposure to
bacteria found within the hospital environment.
“It has become clear that there is a gap in the protection of
patients from exposure to bacteria before a surgical
procedure, and that gap can be filled
by MediClear PreOp,” said Brian Pedlar, Chief Executive
Officer of Covalon. “Clinicians in our surveys at recent
industry events have identified the need for a solution that
bridges the use of presurgical wipes at home and the presurgical
prep of the patient done in the surgical suite. Patients are also
becoming aware of the risks of exposure to hospital-acquired
infectious pathogens and are demanding protection to reduce their
risk of contracting an infection during surgical
procedures. MediClear PreOp satisfies the needs of
both clinicians and patients and can help save lives as a major
preventative force against SSIs.”
Covalon surveyed dozens of clinical Key Opinion Leaders at
last month’s American Association of Orthopedic Surgeons Annual
Conference in Las Vegas, NE, with attendees including industry
leaders in orthopedic surgery and key decision makers from
healthcare institutions across the United States. The results of
the surveys indicated that there was no consistent protocol or
method of protecting patients from exposure to hospital-borne
bacteria from the pre-surgical admitting process up to their
entrance into the sterile operating room. Many of the
Key Opinion Leaders surveyed recognized the value of
using MediClear PreOp in conjunction with their
current infection prevention protocols to better protect patients
in the hospital prior to surgery.
Covalon will further validate the
need for MediClear PreOp at the Association
of periOperative Nurses Global Surgical Conference &
Expo (“AORN”) from April 6-10 at the Music City Centre in
Nashville, TN. AORN will bring together 10,000
perioperative nurses and exhibitors for five days of learning.
Brian Pedlar continued, “Our discussions with orthopedic
surgeons have identified the clear need for an innovative product
like MediClear PreOp. We anticipate that our discussions
with perioperative nurses will provide continued education and
identification of the need for MediClear PreOp to
further protect patients.”
Since Covalon’s launch of this innovative product,
the medical technology industry has
recognized MediClear PreOp as an innovative
presurgical protocol with a number of awards.
MediClear PreOp was the recipient of the 2018 New Product
Innovation Award for Surgical Site Infection Prevention by Frost
& Sullivan and was awarded the 2018 Silver Award by Medical
Design Excellence Awards in the Over-the-Counter Category.
MediClear PreOp is based
on Covalon’s proprietary antimicrobial silicone adhesive
technology and harnesses the synergistic effects of
silver and chlorhexidine, killing 99.99% of microorganisms
associated with SSIs on patients’ skin within 30 minutes of
application and suppressing regrowth until surgery. Clinical
evidence of well-known antimicrobial agents, such as chlorhexidine,
in washes and wipes has shown that they are effective at reducing
the levels of bacteria on a patient’s skin pre-operatively and
subsequently decreasing the incidence of SSIs
when utilized correctly.
Most SSIs are caused by the native flora of the patient’s
skin, mucous membranes, or hollow viscera.4 When the skin
is incised, the underlying tissue is exposed to endogenous flora,
increasing the risk of potential infection. It has been shown that
preoperative skin preparation products containing chlorhexidine,
like MediClear PreOp, help to decrease endogenous and
exogenous pathogens, reduce the risk of SSIs and subsequent
mortality.5 Furthermore, MediClear PreOp’s soft
silicone adhesive is gentle on the skin, while the breathable
polyurethane backing provides a physical barrier to external
contamination, such as bacteria, yeast, and viruses.
To learn more about Covalon, please contact:
Brian Pedlar, CEO, Covalon Technologies Ltd. Email:
bpedlar@covalon.com
Phone: 905.568.8400 x 233 Toll free: 1.877.711.6055 Web site:
www.covalon.com
Twitter: @covalon
References:
1. Watanabe A. Kohnoe S. Shimabukuro R, et al.,
Risk factors associated with surgical site infection in upper and
lower gastrointestinal surgery. Surg Today. 2008, 38, 404-412.
2. World Health Organization. WHO guidelines for safe
surgery: surgery saves lives. 2009. Retrieved Jan 2, 2014 from:
http://apps.who.int/iris/bitstream/10665/44185/1/9789241598552_eng.pdf
3. Scott, D, The Direct Medical Costs of
Healthcare-Associated Infections in US Hospitals and the Benefits
of Prevention, Division of Healthcare Quality Promotion National
Center for Preparedness, Detection, and Control of Infectious
Diseases Coordinating Center for Infectious Diseases Centers for
Disease Control and Prevention March 2009.
4. Altemeir WA, Culbertson WR, Hummel RP, Surgical
consideration of endogenous infections-sources, types and methods
of control. Surg Clin North Am. 1968, 48, 227-240.
5. Eiselt D, Presurgical skin preparation with a novel
2% chlorhexidine gluconate cloth reduces rates of surgical site
infection in orthopaedic surgical
patients. Orthop Nurs 2009, 28, 141-145.
About Covalon
Covalon Technologies Ltd. researches, develops, and
commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products, and
services address the advanced healthcare needs of medical device
companies, healthcare providers, and individual consumers.
Covalon's technologies are used to prevent, detect, and manage
medical conditions in specialty areas such as infection control,
vascular access, surgical procedures, advanced wound care, and
medical device coatings. To learn more about Covalon, visit our
website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including completion of
integration of the AquaGuard acquisition, the difficulty in
predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190408005432/en/
Brian Pedlar, CEO, Covalon Technologies Ltd.Email:
bpedlar@covalon.comPhone: 905.568.8400 x 233Toll free:
1.877.711.6055Web site: www.covalon.comTwitter: @covalon
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Sep 2023 to Sep 2024